Ma X-M, Sun X, Yang G-W, Yu M-W, Zhang G-L, Yu J, Zhang Y, Wang X-M
a School of Graduates , Beijing University of Chinese Medicine , Beijing , China.
b Department of Oncology , Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University , Beijing , China.
Climacteric. 2017 Oct;20(5):448-455. doi: 10.1080/13697137.2017.1326894. Epub 2017 Jun 1.
The platelet-to-lymphocyte ratio (PLR) is a predictive clinical biomarker for different cancers. However, the results of several studies investigating the association between the PLR and the prognosis of ovarian cancer have been inconclusive. Therefore, there is a need to conduct a meta-analysis to estimate the prognostic value of the PLR in ovarian cancer.
We searched the EMBASE, Medline, PubMed, and Web of Science databases to identify clinical studies that had evaluated the association between the PLR and ovarian cancer prognosis. Outcomes evaluated included overall survival (OS) and progression-free survival (PFS). We also analyzed PLR differences between malignant ovarian masses and the controls.
Twelve relevant studies that comprised 2340 patients were selected for the meta-analysis. The results revealed that elevated PLR was significantly associated with poor OS (hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.05-2.56, p < 0.01) and PFS (HR 1.61, 95% CI 1.03-2.51, p < 0.01). The PLRs in malignant cases were higher than in controls (mean difference = 63.57, 95% CI 39.47-87.66, p < 0.00001).
An elevated PLR is associated with poor prognosis in patients with ovarian cancer. The PLR could be employed as a prognostic marker in patients with ovarian cancer.
血小板与淋巴细胞比值（PLR）是不同癌症的一种预测性临床生物标志物。然而，几项研究血小板与淋巴细胞比值和卵巢癌预后之间关联的结果尚无定论。因此，有必要进行一项荟萃分析来评估PLR在卵巢癌中的预后价值。
我们检索了EMBASE、Medline、PubMed和Web of Science数据库，以确定评估PLR与卵巢癌预后之间关联的临床研究。评估的结局包括总生存期（OS）和无进展生存期（PFS）。我们还分析了恶性卵巢肿块与对照组之间的PLR差异。
12项包含2340例患者的相关研究被选入荟萃分析。结果显示，PLR升高与较差的总生存期（风险比（HR）1.63，95%置信区间（CI）1.05 - 2.56，p < 0.01）和无进展生存期（HR 1.61，95% CI 1.03 - 2.51，p < 0.01）显著相关。恶性病例的PLR高于对照组（平均差值 = 63.57，95% CI 39.47 - 87.66，p < 0.00001）。
PLR升高与卵巢癌患者的不良预后相关。PLR可作为卵巢癌患者的一种预后标志物。
